Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting.
Tong J Gan, Kumar G Belani, Sergio Bergese...
https://pubmed.ncbi.nlm.nih.gov/32467512/Actively Recruiting
Led by Beijing Tiantan Hospital · Updated on 2025-09-23
500
Participants Needed
1
Research Sites
4 weeks
Total Duration
Researchers are evaluating the effects and safety of dexamethasone palmitate compared to traditional dexamethasone for preventing postoperative nausea and vomiting PONV after open surgery. Although dexamethasone is commonly used to reduce PONV, some patients still experience symptoms within 24 hours after surgery. Dexamethasone palmitate has a longer-lasting anti-inflammatory effect and fewer side effects, making it a promising option for managing PONV. Participants will be randomly assigned to one of two groups. One group will receive an intravenous injection of dexamethasone palmitate 8 mg containing 5 mg dexamethasone after anesthesia induction and before surgical incision. The other group will receive an intravenous injection of dexamethasone 5 mg at the same time. The trial compares these treatments in patients undergoing elective open surgeries such as spinal, chest, or abdominal surgery. During the study, researchers will monitor participants for the incidence and severity of PONV at multiple time points within 72 hours after surgery. They will also track the use of rescue antiemetic medications, participant satisfaction with PONV management, pain levels using the VAS scale, quality of postoperative recovery, length of hospital stay, and safety outcomes up to one month after surgery. The main outcome is the occurrence of PONV within the first 24 hours postoperatively. Participation lasts through the surgery and follow-up periods as described.
CONDITIONS
Dexamethasone Palmitate for PONV After Open Surgery
F
Fang Luo
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Beijing Tiantan Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - During surgery and immediate postoperative period
Participants receive an intravenous injection of either dexamethasone palmitate or dexamethasone after anesthesia induction and before surgical incision to prevent postoperative nausea and vomiting.
1 treatment visit (in-person)
Duration - Up to 1 month postoperatively
Participants are monitored for postoperative nausea and vomiting, recovery quality, safety outcomes, and satisfaction for up to one month after surgery.
Multiple assessments at 6 hours, 24 hours, 48 hours, 72 hours, discharge, and 1 month postoperatively
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Tong J Gan, Kumar G Belani, Sergio Bergese...
https://pubmed.ncbi.nlm.nih.gov/32467512/Alina Y Rwei, Robert T Sherburne, David Zurakowski...
https://pubmed.ncbi.nlm.nih.gov/29239940/C C Apfel, E Läärä, M Koivuranta...
https://pubmed.ncbi.nlm.nih.gov/10485781/Tong J Gan, Pierre Diemunsch, Ashraf S Habib...
https://pubmed.ncbi.nlm.nih.gov/24356162/Ashraf S Habib, Ya-Ting Chen, Akiko Taguchi...
https://pubmed.ncbi.nlm.nih.gov/16846542/T S Hahm, Justin Sangwook Ko, S J Choi...
https://pubmed.ncbi.nlm.nih.gov/20337618/Tong J Gan
https://pubmed.ncbi.nlm.nih.gov/16717343/Beijing Tiantan Hospital
Lead Sponsor